ALGS FY 2020 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$3M

Operating Income

-$98M

Net Income

-$109M

EPS (Diluted)

$-3.18

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$76M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$265M

Total Liabilities

$45M

Stockholders' Equity

$220M

Cash & Equivalents

$220M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$3M	-$2M	-44.6%
Operating Income	-$98M	-$54M	-81.0%
Net Income	-$109M	-$52M	-107.7%